Qaasid News

Download Our App

Category: 3. Business

  • Rocket Lab Schedules First Dedicated Launch for Japan Aerospace Exploration Agency (JAXA)

    Long Beach, California. November 24, 2025: Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced the launch window for the first of two dedicated Electron launches with the Japan Aerospace Exploration Agency (JAXA).

    The mission, named “RAISE And Shine”, will launch from Rocket Lab Launch Complex 1 in New Zealand during a launch window that opens on December 5 UTC. The mission will deploy the agency’s RApid Innovative payload demonstration SatellitE-4 (RAISE-4) spacecraft, a single satellite that will demonstrate eight technologies developed by private companies, universities, and research institutions throughout Japan. 

    “RAISE And Shine” is the first of two dedicated launches for JAXA’s Innovative Satellite Technology Demonstration Program, an initiative by the agency to demonstrate new and innovative capabilities and technologies developed by Japan’s space economy. The second dedicated launch on Electron for the program is scheduled take place from Q1 2026. The missions are Rocket Lab’s first dedicated Electron launches directly contracted with JAXA, emphasizing Electron’s importance to reliable global space access for both domestic and allied international space agencies. 

    “RAISE And Shine” is also scheduled to be Rocket Lab’s 19th launch this year, continuing Rocket Lab’s record-breaking run of dedicated launches in a single year. Electron’s launch cadence has increased every year since its first launch as global demand continues to rise for dedicated launch to space for government and commercial small satellites.

    “RAISE And Shine” launch information: https://rocketlabcorp.com/missions/next-mission/ 

    “RAISE And Shine” launch window:

    ·         03:00 UTC, December 5

    ·         4:00 p.m. NZDT, December 5

    ·         12:00 p.m. JST, December 5

    ·         10:00 p.m. ET, December 4

    ·         7:00 p.m. PT, December 4

     

    ENDS

    Rocket Lab Media Contact
    Murielle Baker
    media@rocketlabusa.com

    About Rocket Lab
    Rocket Lab is a leading space company that provides launch services, spacecraft, payloads and satellite components serving commercial, government, and national security markets. Rocket Lab’s Electron rocket is the world’s most frequently launched orbital small rocket; its HASTE rocket provides hypersonic test launch capability for the U.S. government and allied nations; and its Neutron launch vehicle in development will unlock medium launch for constellation deployment, national security and exploration missions. Rocket Lab’s spacecraft and satellite components have enabled more than 1,700 missions spanning commercial, defense and national security missions including GPS, constellations, and exploration missions to the Moon, Mars, and Venus. Rocket Lab is a publicly listed company on the Nasdaq stock exchange (RKLB). Learn more at www.rocketlabcorp.com.

    Forward Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at www.rocketlabcorp.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Continue Reading

  • Brightstar Lottery Enhances Retail Lottery Experience in Malaysia with Delivery of 1,200 New Terminals

    Brightstar Lottery Enhances Retail Lottery Experience in Malaysia with Delivery of 1,200 New Terminals

    LONDON, Nov. 24, 2025 /PRNewswire/ — Brightstar Lottery PLC (NYSE: BRSL) (“Brightstar”) announced today that it has signed a contract with Pan Malaysian Pools SDN BHD (“PMP”), a licensed numbers forecast operator in Malaysia, to supply and deliver 1,200 Retailer Pro S2 terminals as part of PMP’s ongoing quest to upgrade its business infrastructure. The Retailer Pro S2 offers high performance, reliability, and a variety of options and peripherals to meet the current and future needs of lotteries and retailers.

    “Deploying Brightstar’s Retailer Pro S2 terminals will provide several added benefits for PMP, our retailers, and players,” said Tan Kong Han, PMP Managing Director. “The many components of this sophisticated terminal will support PMP in our efforts to offer modern experiences for our players, reliable solutions for retailers, and enhance productivity and profitability in our business that continuously funds The Community Chest, which establishes and develops schools throughout Malaysia.”

    “Brightstar’s Retailer Pro S2 represents the next-generation evolution of our industry-leading Retailer Pro terminal, now more compact, powerful, and flexible,” said Marco Tasso, Brightstar Chief Operating Officer International and Italy Operations. “Designed for dynamic retail environments like those in Malaysia, the S2 redefines player engagement by offering a range of interactive options that elevate the experience for PMP’s players.”

    Engineered for speed and reliability, the Retailer Pro S2 features a 15.6″ full HD clerk-facing touchscreen and is powered by a high-performance processor that ensures rapid transaction processing. Its ergonomic, modular design supports multiple player-facing displays and a broad range of peripherals – including barcode scanners, fingerprint readers, NFC technology, and webcams – enabling flexible and engaging player interactions. This next-generation terminal reflects Brightstar’s commitment to innovation and operational excellence across diverse retail environments.

    Brightstar serves nearly 90 lottery customers and their players on six continents. It is the primary technology provider to 26 of the 46 lottery jurisdictions in the U.S. and eight of the world’s 10 largest lotteries.

    For more information, visit us at brightstarlottery.com or follow along on LinkedIn.

    About Brightstar Lottery PLC
    Brightstar Lottery PLC (NYSE: BRSL) is an innovative, forward-thinking global leader in lottery that builds on our renowned expertise in delivering secure technology and producing reliable, comprehensive solutions for our customers. As a premier pure play global lottery company, our best-in-class lottery operations, retail and digital solutions, and award-winning lottery games enable our customers to achieve their goals, entertain players and distribute meaningful benefits to communities. Brightstar has a well-established local presence and is a trusted partner to governments and regulators around the world, creating value by adhering to the highest standards of service, integrity, and responsibility. Brightstar has approximately 6,000 employees. For more information, please visit www.brightstarlottery.com.

    Cautionary Statement Regarding Forward-Looking Statements
    This news release may contain forward-looking statements (including within the meaning of the Private Securities Litigation Reform Act of 1995) concerning Brightstar Lottery PLC and its consolidated subsidiaries (the “Company”) and other matters. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, products and services, customer relationships, results of operations, or financial condition, or otherwise, based on current beliefs of the management of the Company as well as assumptions made by, and information currently available to, such management. Forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “plan,” “could,” “would,” “should,” “shall,” “continue,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project” or the negative or other variations of them. These forward-looking statements speak only as of the date on which such statements are made and are subject to various risks and uncertainties, many of which are outside the Company’s control. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may differ materially from those predicted in the forward-looking statements and from past results, performance, or achievements. Therefore, you should not place undue reliance on such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include (but are not limited to) macroeconomic, regulatory and political uncertainty, including as a result of new or increased tariffs, trade wars, and other restrictions on trade between or among countries in which the Company operates, and related changes in discretionary consumer spending and behavior, fluctuations in foreign currency exchange rates, and the other factors and risks described in the Company’s annual report on Form 20-F for the financial year ended December 31, 2024 and other documents filed or furnished from time to time with the SEC, which are available on the SEC’s website at www.sec.gov and on the investor relations section of the Company’s website at www.brightstarlottery.com. Except as required under applicable law, the Company does not assume any obligation to update these forward-looking statements. You should carefully consider these factors and other risks and uncertainties that may affect the Company’s business. All forward-looking statements contained in this news release are qualified in their entirety by this cautionary statement. All subsequent written or oral forward-looking statements attributable to the Company, or persons acting on its behalf, are expressly qualified in their entirety by this cautionary statement.

    Contact:
    Mike DeAngelis, Corporate Communications, +1 (401) 392-1000, [email protected]
    Matteo Selva, Italian media inquiries, +39 366 6803635
    James Hurley, Investor Relations, +1 (401) 392-7190

    © 2025 Brightstar Lottery PLC

    The trademarks and/or service marks used herein are either trademarks or registered trademarks of Brightstar Lottery PLC, its affiliates or its licensors.

    SOURCE Brightstar Lottery PLC

    Continue Reading

  • Apple cuts jobs across sales team – Reuters

    1. Apple cuts jobs across sales team  Reuters
    2. Apple confirms recent sales team layoffs in uncharacteristic move  9to5Mac
    3. Apple Cuts Dozens of Sales Roles Despite Record Revenue Forecast [Report]  iClarified
    4. Apple cuts sales jobs in rare layoff  Sherwood News
    5. Apple (AAPL) Cuts Jobs in Sales Division  TipRanks

    Continue Reading

  • AMGEN TO PRESENT AT CITI’S 2025 GLOBAL HEALTHCARE CONFERENCE| Amgen

    AMGEN TO PRESENT AT CITI’S 2025 GLOBAL HEALTHCARE CONFERENCE| Amgen

    THOUSAND OAKS, Calif., Nov. 24, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at Citi’s 2025 Global Healthcare Conference at 1:45 p.m. ET on December 3, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

    The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen‘s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

    About Amgen

    Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. 

    In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. 

    For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, YouTube and Threads.

    CONTACT: Amgen, Thousand OaksElissa Snook, 609-251-1407 (media) Casey Capparelli, 805-447-1746 (investors)  

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2025-global-healthcare-conference-302623658.html

    SOURCE Amgen


    Continue Reading

  • Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

    Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

    Vorasidenib (Voranigo) was associated with lower volumetric tumor growth rates (TGR) compared with placebo in patients with grade 2 glioma harboring IDH1/2 mutations, according to data from exploratory analyses from the phase 3 INDIGO trial (NCT04164901) presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.

    Across linear, biexponential, and velocity of diametric expansion (VDE) modeling approaches, patients receiving vorasidenib exhibited substantially lower on-treatment TGRs than those receiving placebo, with these differences translating into clinically meaningful improvements in progression-free survival (PFS) and time to next intervention (TTNI).

    Using linear TGR, vorasidenib produced a mean on-treatment tumor growth of 0.4 mL per 6 months (95% CI, –0.2 to 1.0) compared with 2.7 mL per 6 months (95% CI, 1.9-3.4) for placebo (difference, –2.3; 95% CI, –3.3 to –1.4; P < .001). Multivariable Cox modeling showed that each 1-mL per 6-month increase in TGR increased the risk of progression by 4.6% and the risk of requiring next intervention by 5.1%. Within this study, vorasidenib significantly reduced the risks of PFS (HR, 0.376; 95% CI, 0.268-0.526) and TTNI (HR, 0.276; 95% CI, 0.177-0.431).

    “On-treatment TGR is a strong predictor of PFS and TTNI,” lead study investigator Benjamin M. Ellingson, PhD, MS, and colleagues wrote in a poster presentation of the data. “In patients with IDH1/2[-mutant] glioma enrolled into the INDIGO trial, on-treatment TGR was substantially lower in those receiving vorasidenib than in those receiving placebo, as measured using 3 different approaches.”

    Ellingson currently serves as director of MRI Research and a professor of radiology, psychiatry, bioengineering, and neurosurgery within the David Geffen School of Medicine at the University of California, Los Angeles.

    What previous data were reported from INDIGO?

    In August 2024, the FDA approved vorasidenib for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery, including biopsy, sub-total resection, or gross total resection.2 This decision was based on prior findings from INDIGO, which showed that patients in the vorasidenib arm achieved a median PFS of 27.7 months (95% CI, 17.0–not estimated) compared with 11.1 months (95% CI, 11.0-13.7) for those given placebo (HR, 0.39; 95% CI, 0.27-0.56; P < .001).

    How was the INDIGO TGR analysis conducted?

    This analysis utilized volumetric TGR modeling to evaluate whether early tumor growth dynamics could help predict clinical outcomes in patients with grade 2, IDH1/2-mutated diffuse glioma treated in the phase 3 INDIGO trial. The randomized, placebo-controlled study enrolled adults with grade 2 glioma harboring IDH1/2 mutations, and investigators compared vorasidenib, an oral brain-penetrant IDH1/2 inhibitor, with placebo. Tumor volume data from patients assigned to vorasidenib (n = 168) or placebo (n = 163) were analyzed.

    Investigators assessed tumor growth using 3 distinct modeling approaches: a linear regression model measuring growth in mL per six months, a biexponential model incorporating a tumor growth parameter, and a velocity of diametric expansion model quantifying millimeters per year.3 Individual TGRs were derived from volumetric measures obtained during the first 6 months of on-treatment imaging. These TGR metrics were then correlated with PFS and TTNI to determine their predictive relevance for treatment outcomes in this molecularly defined glioma population.

    What Did the Biexponential TGR Analyses Reveal About Survival Outcomes?

    Consistent findings were observed using biexponential modeling: mean tumor growth (g-value) was lower with vorasidenib (0.00097; 95% CI, 0.00079-0.00114) vs placebo (0.00125; 95% CI, 0.00110-0.00141; P = .0197), and slower-growing tumors were associated with superior PFS and TTNI.1 VDE analysis similarly demonstrated a marked difference in tumor expansion velocity between treatment arms, with a mean on-treatment VDE of 0.2 mm/year (95% CI, –0.3 to 0.6) for vorasidenib vs 3.1 mm/year (95% CI, 2.6-3.6) for placebo (P < .001).

    What Did the VDE Analyses Reveal About Progression Risk in INDIGO?

    The VDE analysis further demonstrated that on-treatment tumor growth dynamics strongly correlate with clinical outcomes in the INDIGO trial. Using linear regression modeling to characterize individual tumor expansion rates, vorasidenib markedly reduced on-treatment VDE compared with placebo, with a mean VDE of 0.2 mm per year (95% CI, –0.3 to 0.6) in the vorasidenib arm vs 3.1 mm per year (95% CI, 2.6-3.6) in the placebo, reflecting a significant mean difference of –2.9 mm per year (P < .001).

    When VDE values were stratified into clinically relevant categories, slower expansion rates consistently aligned with improved PFS and TTNI. Patients with the lowest VDE (≤ –0.50 mm/year) demonstrated the most favorable outcomes, whereas those with rapid tumor expansion (>3.13 mm/year) experienced markedly shorter PFS (median, 8.4 months) and TTNI (median, 12.0 months). Intermediate ranges (>1.27 to ≤3.13 mm/year) also conveyed reduced benefit, with a median TTNI of 28.8 months.

    References

    1. Ellingson BM, Wang L, Vangel MG, et al. Volumetric tumor growth rate modeling predicts clinical outcomes in patients with grade 2 IDH1/2–mutant glioma receiving vorasidenib or placebo in the phase 3 INDIGO trial. Presented at: 2025 SNO Annual Meeting; November 19-23, 2025; Honolulu, HI. Abstract IMG-99.
    2. FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. FDA. August 6, 2024. Accessed November 24, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation
    3. Study of vorasidenib (AG-881) in participants with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation (INDIGO). Clinicaltrials.gov Updated April 3, 2025. Accessed November 24, 2025. https://clinicaltrials.gov/study/NCT04164901

    Continue Reading

  • Agilent beats quarterly revenue estimates on strong demand for lab tools – Reuters

    1. Agilent beats quarterly revenue estimates on strong demand for lab tools  Reuters
    2. Agilent (A) Q4 Earnings on the Horizon: Analysts’ Insights on Key Performance Measures  Nasdaq
    3. Agilent Technologies Stock (A) Eyeing New Highs Ahead of Earnings – What To Expect  AskTraders.com
    4. What To Expect From Agilent’s (A) Q3 Earnings  TradingView
    5. Agilent (A) Set to Announce Earnings with Consensus Estimate  GuruFocus

    Continue Reading

  • DEFENDER TROPHY: FIRST ENTRANT SELECTED FOR EPIC 2026 ADVENTURE

    About The Defender Brand
    The Defender Brand embraces the impossible. Each member of the Defender family is purposefully designed, highly desirable and seriously durable. A modern‑day hero that respects the past but at the same time anticipates the future.

    Available in 90, 110 and 130 body styles, with up to eight seats, each has a charisma of its own.

    The tough luxury Defender OCTA is the master of performance – taking performance and capability to another level on and off‑road. 

    A beacon of liberty that can trace its roots back to the first Land Rover in 1948, Defender is a brand that supports humanitarian and conservation work with the International Federation of Red Cross and Red Crescent Societies and the Tusk Trust. 

    The Defender brand is underpinned by Land Rover – a mark of trust built on more than 75 years of expertise in technology and world‑leading off‑road capability. 

    The Defender brand is designed and engineered in the UK and sold in 121 countries. It belongs to the JLR house of brands alongside Range Rover, Discovery and Jaguar.

     

    Important notice
    JLR is constantly seeking ways to improve the specification, design and production of its vehicles, parts and accessories and alterations take place continually. Whilst every effort is made to produce up‑to‑date literature, this document should not be regarded as an infallible guide to current specifications or availability, nor does it constitute an offer for the sale of any particular vehicle, part or accessory. All figures are manufacturer’s estimates.

    Continue Reading

  • UK Government Partners With Private Investment to Keep Quantum Technologies British

    UK Government Partners With Private Investment to Keep Quantum Technologies British

    Insider Brief

    • Quantum Exponential Group signed an MOU with the government-aligned Harwell Quantum Cluster to strengthen domestic support for UK quantum technologies.
    • The partnership aligns QE’s £100 million Quantum Technologies Fund with national facilities such as the NQCC and NPL to address the UK’s scale-up funding gap.
    • The collaboration aims to support more than 100 quantum companies over the next decade by improving investor access to Britain’s quantum infrastructure and ecosystem.

    PRESS RELEASE — Quantum Exponential Group plc (QE) – the UK’s first investor group exclusively focused on quantum technologies – has signed a landmark Memorandum of Understanding (MOU) with the Harwell Quantum Cluster, led by the Science and Technology Facilities Council (STFC), which is part of UK Research & Innovation (UKRI). The partnership brings QE into closer collaboration with one of the UK’s most important government-backed quantum hubs, located on the Harwell Science and Innovation Campus.

    The agreement addresses a critical challenge facing British deep-tech startups: the scale-up funding gap that risks homegrown technologies being acquired by foreign investors or relocating overseas, as highlighted by a recent RUSI report. The MOU coincides with QE’s new £100 million Quantum Technologies Fund, created to address the scale-up funding gap that threatens the UK’s ability to compete in the global quantum race.

    Protecting UK quantum sovereignty through strategic investment

    The Harwell Quantum Cluster is a flagship national environment for quantum innovation. It brings together STFC; the Harwell Joint Venture (Brookfield Asset Management and the UK Atomic Energy Authority); the Department for Science, Innovation and Technology (DSIT); and the Department for Business and Trade. The cluster links directly to the National Quantum Computing Centre (NQCC) on the Harwell Campus and works closely with the National Physical Laboratory (NPL), another major DSIT-backed national hub.

    By partnering with this government-aligned infrastructure, QE becomes one of the first private investors to work directly alongside the UK’s national quantum facilities, helping ensure that British quantum breakthroughs translate into British-based companies.

    Steve Metcalfe, CEO of Quantum Exponential, said:

    “Working directly with the Harwell Quantum Cluster and the London Quantum Cluster, together with national facilities including the NQCC, NPL, and the Institute of Physics, creates a clear pathway to keep quantum innovation, jobs, and wealth creation in the UK. Britain leads the world in quantum research, yet without accessible domestic investment we risk seeing our most promising companies bought up overseas. This partnership reinforces the UK’s technological sovereignty and ensures investors can engage with one of the most dynamic sectors in global deep tech.”

    £100 million fund to anchor the UK quantum supply chain

    The fund will deploy around two-thirds of its capital into UK companies emerging from the national quantum ecosystem, supporting startups and accelerating commercialisation while strengthening Britain’s domestic quantum supply chain. This commitment complements UKRI’s long-term government investment and attracts essential private capital to translate research into scalable companies.

    The fund will invest across quantum computing, sensing, communications, and enabling technologies, from seed to scale. QE brings a proven 3.5-year track record, eight revenue-generating portfolio companies, and performance targets in the top quartile of deep-tech funds (25–33% IRR). The strength of the UK’s sector has already helped secure an anchor Letter of Intent from a major Silicon Valley investor.

    Unprecedented access to Britain’s quantum infrastructure

    Under the MOU, QE will work with Harwell leadership to identify early-stage companies within government-backed environments and support their growth across the wider ecosystem, including links to the NQCC, NPL, and STFC’s national laboratories. Investors gain unmatched access to Britain’s most advanced quantum facilities.

    Over the next decade, the Harwell Quantum Cluster aims to grow more than 100 quantum-focused companies, create over 1,000 high-value jobs, and attract more than £1 billion in public and private investment. This partnership directly supports those ambitions.

    QE welcomes interest from family offices, institutional investors, sovereign funds, and strategic industry partners seeking exposure to the emerging global quantum technology sector.

    Continue Reading

  • Amazon to invest $15 billion in Indiana to boost data center infrastructure – Reuters

    1. Amazon to invest $15 billion in Indiana to boost data center infrastructure  Reuters
    2. Amazon plans to invest $15 billion in Northern Indiana to build new data center campuses and advance AI innovation  About Amazon
    3. Delta In a Minute 11-21  deltanews.tv
    4. Amazon to Build $3B AI Data Center in Vicksburg, as Gov. Reeves Proclaims Arrival of the ‘Digital Delta’  Mississippi Free Press
    5. Small businesses see growth from Amazon Web Services construction in Madison County  WLBT

    Continue Reading

  • Three vessels bound for US Gulf Coast terminals to load soybeans, sorghum for China – Reuters

    1. Three vessels bound for US Gulf Coast terminals to load soybeans, sorghum for China  Reuters
    2. Soybeans sit below 17-month highs as traders mull Chinese demand  Business Recorder
    3. China Ramps Up Buying of US Soybeans After Brief Pause in Trade  Bloomberg.com
    4. Soybeans Showing Steady Trade at Midday  Barchart.com
    5. Three vessels bound for US Gulf Coast terminals to load soybeans, sorghum for China By Reuters  Investing.com

    Continue Reading